EGFR mutation-positive NSCLC tumors are highly heterogeneous. therefore. exploring an agent simultaneously targeting multiple EGFR mutations may be valuable for clinical practice. Compared with osimertinib. https://www.voyageassistance.com/product-category/prostate/